IRIS UniCatt

Fianchi, Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.708
EU - Europa 5.746
AS - Asia 4.604
SA - Sud America 889
AF - Africa 120
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 6
Totale 18.095
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.547
DE - Germania 2.198
SG - Singapore 1.980
CN - Cina 1.304
SE - Svezia 816
BR - Brasile 721
IT - Italia 442
FR - Francia 400
NL - Olanda 381
UA - Ucraina 371
VN - Vietnam 358
PL - Polonia 281
GB - Regno Unito 230
IE - Irlanda 200
IN - India 199
ID - Indonesia 133
FI - Finlandia 129
RU - Federazione Russa 120
JP - Giappone 101
HK - Hong Kong 90
BD - Bangladesh 89
IQ - Iraq 64
CA - Canada 63
MX - Messico 60
TR - Turchia 60
AR - Argentina 57
ZA - Sudafrica 36
ES - Italia 30
KR - Corea 30
PK - Pakistan 28
SA - Arabia Saudita 26
CO - Colombia 25
EC - Ecuador 23
BE - Belgio 22
AT - Austria 20
AU - Australia 19
CL - Cile 18
NO - Norvegia 18
JO - Giordania 17
CI - Costa d'Avorio 16
LT - Lituania 15
UZ - Uzbekistan 15
EG - Egitto 14
PH - Filippine 13
KE - Kenya 12
RO - Romania 12
VE - Venezuela 12
CZ - Repubblica Ceca 11
IR - Iran 11
MA - Marocco 11
AE - Emirati Arabi Uniti 10
KZ - Kazakistan 10
PE - Perù 10
CR - Costa Rica 8
GR - Grecia 8
MY - Malesia 8
NP - Nepal 8
PY - Paraguay 8
AZ - Azerbaigian 7
IL - Israele 7
BG - Bulgaria 6
BO - Bolivia 6
LV - Lettonia 6
TH - Thailandia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
ET - Etiopia 5
HU - Ungheria 5
JM - Giamaica 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
OM - Oman 4
PA - Panama 4
AO - Angola 3
BH - Bahrain 3
CH - Svizzera 3
GE - Georgia 3
HR - Croazia 3
TT - Trinidad e Tobago 3
BB - Barbados 2
BW - Botswana 2
EU - Europa 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LU - Lussemburgo 2
LY - Libia 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 18.068
Salva come PNG Salva come JPEG
Città #
Singapore 1.052
Chandler 811
Ashburn 657
San Jose 635
Amsterdam 355
Warsaw 267
Jacksonville 264
Beijing 245
Frankfurt am Main 188
Dublin 187
San Mateo 185
Ann Arbor 172
New York 172
Los Angeles 163
Dearborn 159
Nanjing 157
Wilmington 146
Houston 128
Lauterbourg 121
Jakarta 120
Nürnberg 120
Ho Chi Minh City 118
Chicago 114
Hefei 114
Woodbridge 110
Milan 102
Munich 97
Hanoi 94
Boston 88
Hong Kong 84
Fairfield 81
Tokyo 79
São Paulo 78
Bremen 75
Moscow 73
Buffalo 71
Seattle 70
Lawrence 67
Cattolica 66
St Louis 59
Nanchang 54
Rome 51
Dallas 50
Redwood City 50
Hyderabad 46
Redmond 46
Shanghai 46
Zhengzhou 46
Marseille 45
Santa Clara 42
Council Bluffs 41
The Dalles 41
Hangzhou 38
Shenyang 38
Kunming 37
Princeton 37
Lancaster 35
Tianjin 34
Kent 31
Leawood 30
London 30
Cambridge 29
Da Nang 28
Boardman 27
Izmir 27
Hebei 26
Salt Lake City 26
Auburn Hills 25
Brooklyn 25
Baghdad 24
Guangzhou 24
Jiaxing 24
Rio de Janeiro 24
Atlanta 23
Orem 23
Seoul 23
Brussels 22
Memphis 21
Montreal 21
Mountain View 21
Nuremberg 21
Augusta 20
Helsinki 20
Mexico City 20
Paris 20
Norwalk 19
Philadelphia 19
Pune 19
San Francisco 19
Falls Church 18
University Park 18
Düsseldorf 17
Lappeenranta 17
Poplar 17
Tampa 17
Abidjan 16
Changsha 16
Chatsworth 16
Haiphong 16
Amman 15
Totale 9.635
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 587
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 435
Incidence of acute myeloid leukemia after breast cancer 384
Factors associated with mortality in bacteremic patients with hematologic malignancies. 374
Factors associated with mortality in bacteremic patients with haematologic malignancies 356
Fanconi anemia gene variants in therapy-related myeloid neoplasms 327
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 269
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 241
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 241
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 240
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. 228
Factors associated with mortality in bacteremic patients with hematologic malignancies. 218
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 216
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 211
Why methylation is not a marker predictive of response to hypomethylating agents 202
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 202
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 198
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. 194
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 191
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 190
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 189
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 186
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 185
Epigenetic changes in therapy-related MDS/AML 183
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 183
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 181
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 176
Clonal evolution in therapy-related neoplasms 176
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 175
Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia 174
Similarities and differences between therapy-related and elderly acute myeloid leukemia 171
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 170
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 167
Primary plasma cell leukemia followed by testicular plasmacytoma 165
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 164
Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 161
. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. 159
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 158
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 153
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 152
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 151
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 150
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 149
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 149
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 147
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 146
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 144
Small lymphocytic lymphoma in a patient with Fabry disease 141
Outcome of therapy-related myeloid neoplasms treated with azacitidine 139
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 139
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 139
Scedosporiosis in patients with acute leukemia: a retrospective multicenter report 137
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 137
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 136
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 135
Small lymphocytic lymphoma in a patient with Fabry disease 134
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 134
Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. 132
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 131
Caspofungin for the treatment of candidaemia in patients with haematological malignancies 129
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 128
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 128
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 127
Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia 126
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 125
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) 124
Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? 124
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 123
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. 121
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 121
Therapy-related myeloid neoplasms: Clinical perspectives 119
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 118
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 117
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 114
Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia 114
Current therapeutic approaches to fungal infections in immunocompromised hematological patients 113
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry 112
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study 112
Polymorphisms within the ARNT2 and CX3CR1 Genes Are Associated with the Risk of Developing Invasive Aspergillosis 112
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 112
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 111
CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis 110
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 110
Fungal pneumonia due to molds in patients with hematological malignancies. 109
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 107
Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia 106
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 105
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience 104
The role of neutrophils in the development and outcome of zygomycosis in haematological patients 104
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 104
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 103
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 102
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry 101
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 101
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 101
Therapy-related myeloid neoplasms 99
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 99
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 98
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 97
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 97
Totale 16.189
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.397
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.397
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202134 0 0 0 0 0 0 0 0 0 0 0 34
2021/20221.032 108 70 12 43 75 49 26 164 55 85 143 202
2022/20232.158 273 304 186 382 151 256 81 182 232 17 72 22
2023/2024974 50 273 32 31 29 195 53 23 12 27 126 123
2024/20252.416 60 75 161 49 209 59 109 101 352 218 677 346
2025/20266.300 857 178 342 612 941 827 919 307 490 471 222 134
Totale 18.286